The novel compound CW-33 inhibits EV-A71 viral 2A protease and demonstrates synergistic antiviral activity when combined with low-dose Type I IFN, suggesting potential for developing alternative treatments for EV-A71 infection.
No takes yet. Share an insight, caveat, or question.
CW-33 plus IFN-β warrants further preclinical testing for EV-A71; leaves open clinical translation from animal data.
Wang et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: